Most recently, in vivo studies by Zheng et al. found that a combination of PD-L1 checkpoint inhibition and a novel PRMT1 inhibitor (PT1001B) upregulated tumor-infiltrating CD8 T-cells in pancreatic tumors [124]. Here, PRMT1 is linked to neoplasm.